

**PATENT COOPERATION TREATY**

From the  
INTERNATIONAL SEARCHING AUTHORITY

REC'D 24 MAY 2005  
WIPO

To:

Awapatent AB  
Box 5117  
200 71 Malmö  
Sweden

**PCT**

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

(PCT Rule 43bis.1)

Date of mailing (day/month/year)	
17 -05- 2005	

Applicant's or agent's file reference  
21018060

**FOR FURTHER ACTION**

See paragraph 2 below

International application No. PCT/SE 2005/000054	International filing date (day/month/year) 19.01.2005	Priority date (day/month/year) 04.02.2004
---	--	--

International Patent Classification (IPC) or both national classification and IPC  
A61K 31/4025, 31/155, 31/195,  
C07D207/26, 211/98, 401/12, 403/12, 215/00, A61P 19/00, 37/00, 21/00

Applicant  
Active Biotech AB et al

1. This opinion contains indications relating to the following items:

<input checked="" type="checkbox"/> Box No. I	Basis of the opinion
<input checked="" type="checkbox"/> Box No. II	Priority
<input checked="" type="checkbox"/> Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/> Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/> Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input type="checkbox"/> Box No. VI	Certain documents cited
<input type="checkbox"/> Box No. VII	Certain defects in the international application
<input type="checkbox"/> Box No. VIII	Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further opinions, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/SE  
Patent- och registreringsverket  
Box 5055  
S-102 42 STOCKHOLM  
Facsimile No. +46 8 667 72 88

Authorized officer

Fernando Farieta/ELY  
Telephone No. +46 8 782 25 00

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/SE 2005/000054

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.  
 This opinion has been established on the basis of a translation from the original language into the following language, \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material  
 a sequence listing  
 table(s) related to the sequence listing
  - b. format of material  
 in written format  
 in computer readable form
  - c. time of filing/furnishing  
 contained in the international application as filed.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority for the purposes of search.
3.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/SE 2005/000054

Box No. II Priority

1.  The following document has not yet been furnished:
  - copy of the earlier application whose priority has been claimed (Rules 43bis.1 and 66.7(a)).
  - translation of the earlier application whose priority has been claimed (Rules 43bis.1 and 66.7(b)).Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.
2.  This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.
3. Additional observations, if necessary:

The priority is considered valid.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/SE 2005/000054

**Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The question whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

the entire international application  
 claims Nos. 14-16

because:

the said international application, or the said claims Nos. 14-16  
 relate to the following subject matter which does not require an international preliminary examination (specify):

See PCT Rule 67.1.(iv)..: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_\_\_\_\_  
 are so unclear that no meaningful opinion could be formed (specify):

The claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported  
 by the description that no meaningful opinion could be formed.

no international search report has been established for said claims Nos. \_\_\_\_\_

the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:  
 the written form  has not been furnished  
 does not comply with the standard  
 the computer readable form  has not been furnished  
 does not comply with the standard

the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in the Annex C-bis of the Administrative Instructions.

See Supplemental Box for further details.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/SE 2005/000054

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
1. Statement			
Novelty (N)	Claims	1-13	YES
	Claims		NO
Inventive step (IS)	Claims	1-13	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-13	YES
	Claims		NO
2. Citations and explanations:			
Documents cited in the International Search Report:			
D1: WO 99/63929 A3			
D2: WO 99/12912 A1			
D3: WO 93/16992 A1			
D4: EP 0325 397 A1			
<p>The cited documents represent the general state of the art. The invention defined in claims 1-13 is not disclosed by any of these documents.</p> <p>The cited prior art does not give any indication that would lead a person skilled in the art to the claimed diureas. Therefore, the claimed invention is not obvious to a person skilled in the art.</p> <p>Accordingly, the invention defined in claims 1-13 is novel and is considered to involve an inventive step. The invention is industrially applicable.</p>			